Melasma trial: laser vs tranexamic acid injection and pills
Treatments studied
Part of Skin clinical trials.
This trial compares a laser treatment (fractional erbium YAG) with tranexamic acid given as a shot or pill for melasma. It aims to find which option works better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melasma (dark patches on your face or skin).
- You are not pregnant or breastfeeding.
- You haven't taken birth control pills or any drugs that make you sensitive to sunlight in the past month.
- You do not have a history of blood clots, abnormal bleeding, allergy to tranexamic acid or hydroquinone, or any endocrine (hormone) disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two oral treatments—melatonin and tranexamic acid—to see which works better for reducing melasma. Both are pills you take by mouth, and the goal is to find a safe, effective option for people with this skin condition.
This trial tests two injectable treatments for melasma (dark patches on the face): platelet-rich fibrin, which uses your own blood cells to promote healing, and tranexamic acid, a medication that may reduce pigmentation. The study will compare which works better for women with mild to moderate melasma.
This trial compares two treatments for melasma, a common skin condition causing dark patches on the face. One treatment uses an injection into the affected skin (tranexamic acid), while the other uses a chemical peel (mandelic acid). The study aims to see which works better and is safer for people with darker skin tones.
This trial tests whether a cream containing metformin or tranexamic acid can reduce melasma (dark patches on the face). It aims to see which treatment works better.
This study tests whether combining oral tranexamic acid with a special skin needling treatment helps reduce melasma (dark facial patches). It is designed for women aged 18-50 who have melasma and are not pregnant or on certain medications.
This trial tests a new way to deliver a medicine (tranexamic acid) into melasma patches using ultrasound waves. It aims to see if the ultrasound helps the medicine work better to lighten the dark spots.
Hear when a new Refractory Melasma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.